Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Gene therapy symbols : PFE save search
Voyager Therapeutics Announces License Option Agreement with Pfizer for Next-Generation TRACERᵀᴹ AAV Capsids to Enable Neurologic and Cardiovascular Gene Therapy Programs
Published: 2021-10-06 (Crawled : 12:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: -0.61%
H: 0.33%
C: -0.1%
VYGR | $7.55 -2.46% -2.52% 1M
|
Health Technology
|
| O: 61.54%
H: 3.26%
C: -3.01%
cardiovascular gene therapy therapy license cardio aav9 gene therapies aav capsids
Cell and Gene Therapy Drug Delivery Devices Market, 2030 - Market Opportunities in the Strong Pipeline of Cell and Gene Therapies
Published: 2021-03-30 (Crawled : 22:00) - prnewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.11%
H: 0.77%
C: 0.22%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -1.55%
H: 0.51%
C: -0.22%
BDX | $233.15 0.41% 0.15% 890K
|
Health Technology
|
| O: -0.01%
H: 0.25%
C: -0.82%
VCEL | $43.86 -5.19% -5.47% 430K
|
Health Technology
|
| O: 0.74%
H: 5.83%
C: 4.75%
QURE | $4.71 0.86% 0.85% 440K
|
Health Technology
|
| O: -0.81%
H: 4.45%
C: 2.03%
ORTX | $16.7 0.0% 370K
|
Health Technology
|
| O: -0.7%
H: 4.08%
C: 2.25%
BLUE | $0.9583 -0.52% -0.52% 6.5M
|
Health Technology
|
| O: 0.66%
H: 5.38%
C: 4.65%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: -0.21%
H: 0.29%
C: -0.17%
gene therapies gene therapy therapy drug device drug delivery liver
Global Cell and Gene Therapy Market Report 2021-2027: Market Opportunities in Drug Approvals and Strong Pipeline & Increasing Number of Mergers and Acquisitions
Published: 2021-03-08 (Crawled : 13:14) - prnewswire.com
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.26%
H: 1.13%
C: -0.38%
NVS | News | $92.57 -0.55% 0.0% 910K
|
Health Technology
|
| O: -0.02%
H: 0.89%
C: -0.31%
ORGO | $2.865 2.69% 2.62% 330K
|
Finance
|
| O: 1.86%
H: 1.82%
C: -2.21%
AMGN | $262.77 -0.49% -0.49% 2M
|
Health Technology
|
| O: 0.15%
H: 1.81%
C: -0.12%
acquisition gene therapy therapy acquisitions drug merge approval gene therapies
Pfizer Doses First Participant in Phase 3 Study for Duchenne Muscular Dystrophy Investigational Gene Therapy
Published: 2021-01-07 (Crawled : 19:00) - biospace.com/
PFE A | $25.39 -0.12% -0.12% 36M
|
Health Technology
|
| O: 0.46%
H: 0.3%
C: 0.05%
gene therapy therapy phase 3 duchenne gene therapies
Gainers vs Losers
| 64% | 36% |
Top 10 Gainers
AGBA | $1.02 155.0% 57.94% 120M
|
Finance
ZCMD | $2.86 108.76% 52.1% 2.3M
|
Commercial Services
INVO | $1.555 104.6% 51.13% 5M
|
Health Technology
ISPC | $0.437 105.16% 49.53% 37M
|
Professional, Scientific, and T...
WLGS | $0.92 84.0% 45.65% 1.6M
|
OST | $0.499 21.38% 45.26% 1.9M
|
XPON | $3.1 60.62% 37.74% 17M
|
TIRX | $0.7 44.39% 30.74% 58M
|
BNTC | $6.92 44.17% 30.64% 3.5M
|
Health Technology
GGE | $0.035 19.86% 29.3% 64M
|
Your saved searches
Save your searches and get alerts when important news are released.